Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678920 | 1.00 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL30515161 | 1.00 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL4679073 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL30515117 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL4680474 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL18095621 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL4680901 | 0.94 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL4680792 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL6816601 | 0.94 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL4092286 | 0.93 | PPARG (0.87) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1414809-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER CORP (US) | 2008-03-12 | — | — | EP | disclosed |
| US-7112597-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060205723-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-6828335-B2 | Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis | BAYER PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| WO-2004082601-A2 | METHOD OF TREATING DIABETES AND DIABETES-RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-1414809-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC | 2003-11-20 | — | — | US | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205723-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARA 365/4885PPARG 578/4885 |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARA 365/4885PPARG 578/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PPARA 534/4885PPARG 988/4885 |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885 |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885 |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885 |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARA 365/4885PPARG 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.